title: RNA-based vaccines.
abstract: Nucleic acid vaccines consisting of plasmid DNA, viral vectors or RNA may change the way the next generation vaccines are produced, as they have the potential to combine the benefits of live-attenuated vaccines, without the complications often associated with live-attenuated vaccine safety and manufacturing. Over the past two decades, numerous clinical trials of plasmid DNA and viral vector-based vaccines have shown them to be safe, well-tolerated and immunogenic. Yet, sufficient potency for general utility in humans has remained elusive for DNA vaccines and the feasibility of repeated use of viral vectors has been compromised by anti-vector immunity. RNA vaccines, including those based on mRNA and self-amplifying RNA replicons, have the potential to overcome the limitations of plasmid DNA and viral vectors. Possible drawbacks related to the cost and feasibility of manufacturing RNA vaccines are being addressed, increasing the likelihood that RNA-based vaccines will be commercially viable. Proof of concept for RNA vaccines has been demonstrated in humans and the prospects for further development into commercial products are very encouraging.
authors.affiliation: Novartis Vaccines, Cambridge, MA 02139, USA. jeffrey.ulmer@novartis.com
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Ulmer
authors.forename: Peter W
authors.initials: PW
authors.lastname: Mason
authors.forename: Andrew
authors.initials: A
authors.lastname: Geall
authors.forename: Christian W
authors.initials: CW
authors.lastname: Mandl
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D005822:Genetic Vectors / Q000276:immunology*; D006801:Humans; D010957:Plasmids / Q000276:immunology; D012313:RNA / Q000276:immunology*; D012093:Replicon / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology*
chemical_list: D019444:Vaccines, DNA; D012313:RNA